Evolus (EOLS) Stock Price
$9.26 1.3%
to add to portfolio
AI Score

-
Alternative
7 -
Fundamental
2 -
Technical
3
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Evolus, AI stock picks, stock alerts and much more.
EOLS AI Stock Analysis
AI stock analysis for EOLS is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Evolus (EOLS) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Evolus (EOLS) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Evolus (EOLS), currently trading at $9.26, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About EOLS

-
Evolus, Inc.
-
Symbol
EOLS
-
Market
NASDAQ
-
Industry
Drug Manufacturers - Specialty & Generic
-
Market Cap
597M
Similar Stocks
![]() |
TherapeuticsMD TXMD |
$1.18 0.9% |
3 |
![]() |
Tilray TLRY |
$0.5903 17.3% |
3 |
![]() |
Canopy Growth CGC |
$1.23 2.5% |
3 |
![]() |
Aurora Cannabis ACB |
$4.56 2.9% |
4 |
![]() |
Sundial Growers SNDL |
$1.38 11.3% |
3 |
News
EOLS Alternative Data
Web Traffic
Evolus receives an estimated 46278 monthly visitors to Evolus.com.
-
Web Traffic
46278
-
Change from Previous Month
0.4%
-
3 Month Change
15.4%
-
YoY Change
15.4%
Twitter Followers
Evolus has 709 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.3% over the last month.
-
Twitter Followers
709
-
Daily Change
0%
-
1 Month Change
0.3%
-
3 Month Change
1.4%
-
YoY Change
1.4%
Facebook Engagement
Evolus has engaged 7 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
7
-
Daily Change
22.2%
-
1 Month Change
16.7%
-
3 Month Change
36.4%
-
YoY Change
36.4%
Instagram Followers
Evolus has 55,304 Instagram Followers on its main Instagram account, up by 0.8% over the last month.
-
Instagram Followers
55304
-
Daily Change
0%
-
1 Month Change
0.8%
-
3 Month Change
4%
-
YoY Change
4%
LinkedIn Followers
25,908 are following Evolus on LinkedIn, up by 1.7% over the last month.
-
LinkedIn Followers
25908
-
Daily Change
0%
-
1 Month Change
1.7%
-
3 Month Change
6.3%
Job Postings
Evolus has an estimated 14 open job postings, which is down -26.3% over the last month.
-
Job Postings
14
-
Daily Change
6.7%
-
1 Month Change
26.3%
-
3 Month Change
51.7%
-
YoY Change
51.7%
LinkedIn Employees
According to LinkedIn, Evolus has 408 employees, down by -0.5% over the last month.
-
LinkedIn Employees
408
-
Daily Change
0%
-
1 Month Change
0.5%
-
3 Month Change
7.7%
-
YoY Change
7.7%
Reddit Mentions
Evolus has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Business Outlook
According to employee reviews, the business outlook among employees at Evolus is 93 out of 100 (very bullish).
-
Business Outlook
93
-
Change from Previous Month
0%
-
3 Month Change
12%
-
YoY Change
12%
News Mentions
Evolus was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
App Downloads
-
App Downloads
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
EOLS Financials
EOLS Key Metrics
-
Total Revenue
$78.9M
-
Net Income
-$6.8M
-
Earnings per Share
-$0.11
-
Free cash flow
$3.4M
-
EBITDA
-$10.2M
-
EBITDA Ratio
-0.129378
-
Total Assets
$232.6M
EOLS 2-year Revenue & Income
EOLS 2-year Free Cash Flow
EOLS Technicals
EOLS SMA
EOLS RSI
FAQ
What's the current price of Evolus (EOLS) Stock?
The price of an Evolus (EOLS) share is $9.26.
What's the market cap of Evolus?
The current market cap of Evolus is 597M.
Should I buy or sell EOLS?
Evolus shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Evolus is better viewed as a hold or accumulate position while waiting for further developments.
Is Evolus a good investment?
The current analysis of Evolus' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Evolus' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Evolus (EOLS) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Evolus stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Evolus (EOLS) that investors often compare it to?
Evolus (EOLS) is often compared to similar stocks such as TherapeuticsMD, Tilray, Canopy Growth, Aurora Cannabis and Sundial Growers.
What is the forecast for Evolus' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Evolus' stock price to be around $9.57 in 2026. Starting from the current price of $9.26, this represents a 3.3% change in price, indicating a neutral outlook for the stock.
How to buy Evolus (EOLS) Stock?
Evolus stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Evolus shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.